Key result
Mexiletine prevents syncope and shortens QT in a patient with refractory congenital LQTS.
Why the study?
Does mexiletine improve QT interval and prevent syncope in a patient with congenital long QT syndrome refractory to beta-blockers and sympathectomy?
Case Report (n=1)
Does mexiletine improve QT interval and prevent syncope in a patient with congenital long QT syndrome refractory to beta-blockers and sympathectomy?
Mexiletine may be an effective treatment for shortening the QT interval and preventing syncope in congenital long QT syndrome refractory to beta-blockers and sympathectomy.
May support mexiletine in refractory congenital LQTS; hypothesis-generating, requiring prospective trials before practice change.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Jeon et al. (2000) conducted a case report in Congenital long QT syndrome (n=1). Mexiletine was evaluated on QT interval shortening and syncope recurrence. Mexiletine medication significantly shortened the QT interval and prevented further syncope in a 24-year-old female with congenital long QT syndrome refractory to beta-blockers and sympathectomy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: